title: Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
abstract: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation and cyclin D1 over-expression. A biologically and clinically heterogeneous lymphoma, MCL, remains clinically challenging, with no proven curative therapy and no established standard of care. However, there have been considerable advances in the last several years in the treatment and understanding of MCL with the FDA approval of lenalidomide and ibrutinib, the development of other potentially active novel agents and the identification of recurrent mutations through new genomic sequencing approaches that may contribute to the biology of MCL and to therapeutic resistance. At the Lymphoma Research Foundation's 11th MCL Workshop, researchers gathered to discuss recent studies and current issues related to the biology of MCL, novel therapeutic targets and new treatment strategies. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.
authors.affiliation: a University of Wisconsin , Madison , WI , USA.
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
authors.affiliation: b Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center , Chicago , IL , USA.
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.affiliation: c University of Munich-Grosshadern , Munich , Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: d British Columbia Cancer Agency , Vancouver , BC , Canada.
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.affiliation: e H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
authors.forename: Eduardo M
authors.initials: EM
authors.lastname: Sotomayor
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D035843:Biomedical Research / Q000379:methods* / Q000639:trends; D003131:Combined Modality Therapy; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods; D062085:RNA, Long Noncoding / Q000235:genetics; D033581:Stem Cell Transplantation / Q000379:methods*; D016019:Survival Analysis; D014178:Translocation, Genetic; D014182:Transplantation, Autologous
chemical_list: D014408:Biomarkers, Tumor; D062085:RNA, Long Noncoding
keywords: Lymphoma and Hodgkin's disease; immunotherapy; marrow and stem cell transplantation clinical results; pharmacotherapeutics